ReviewInfectious diseases and therapy2026
The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review.
Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones.Pharmaceuticals (Basel, Switzerland) · 2026Review
- From linezolid to contezolid: a strategy for safe continuation of therapy in complex tuberculosis.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tuberculosis (TB) continues to represent a significant global public health concern, with China being a country that bears the burden of a high incidence of TB cases on a global scale. Although linezolid (LZD) has been recommended for treating drug-resistant tuberculosis (DR-TB), its intolerability and adverse events, such as myelosuppression, neurotoxicity, etc., have limited its long-term usage in anti-TB treatment. Contezolid (CZD), a new generation of oxazolidinone drug, shows comparable or superior antibacterial activity to LZD, with lower risks of myelosuppressive toxicity, neurotoxicity, and lactic acidosis. Its unique metabolic pathway and favorable pharmacokinetic profile render it a promising alternative to LZD for TB treatment. Recent years have seen mounting evidence of the potential of CZD in treating TB. In this paper, the development history, the mode of action, resistance mechanisms, and research progress on CZD for TB treatment are reviewed, aiming to enhance understanding of its role in anti-TB therapy and to provide valuable references for clinical use and future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.